{
  "report_rows": [
    {
      "kpi": "Diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$7.75 vs. cons $7.23",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$4.95B vs. cons $4.71B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Remaining performance obligations (RPO)",
      "prediction": "BEAT",
      "answer": "pred ~$16.45B vs. cons $16.05B",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 revenue guidance",
      "prediction": "BETTER",
      "answer": "guide ~$19.45B midpoint vs. cons $19.15B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 diluted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$30.75 midpoint vs. cons $30.59 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 operating-margin guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~9.2% midpoint vs. cons 9.2% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 7.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 9.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Day-1 residual ~+7.5% and 5-day residual ~+9.5%: a material EPS/revenue beat plus a FY2026 guide midpoint of ~$30.75 versus ~$30.59 consensus should drive out-period estimate increases rather than merely a quarterly beat. Continued RPO growth of ~$16.45B versus ~$16.05B supports revenue-conversion visibility, while unchanged ~9.2% margin guidance limits the risk that mix dilution offsets the higher sales outlook.",
  "day5_confidence": "MEDIUM"
}